NASDAQ:RIGL - Nasdaq - US7665597024 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to RIGL. RIGL was compared to 562 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. RIGL is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, RIGL could be worth investigating further for value and growth investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.13% | ||
ROE | 200.24% | ||
ROIC | 31.74% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 21.63% | ||
PM (TTM) | 18.31% | ||
GM | 89.64% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.42 | ||
Debt/FCF | 1.69 | ||
Altman-Z | -7.17 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.2 | ||
Quick Ratio | 2.13 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 19.97 | ||
Fwd PE | 10.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 9.49 | ||
EV/EBITDA | 6.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
18.77
-0.13 (-0.69%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 19.97 | ||
Fwd PE | 10.64 | ||
P/S | 1.65 | ||
P/FCF | 9.49 | ||
P/OCF | 9.42 | ||
P/B | 18.07 | ||
P/tB | N/A | ||
EV/EBITDA | 6.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.13% | ||
ROE | 200.24% | ||
ROCE | 40.18% | ||
ROIC | 31.74% | ||
ROICexc | 107.63% | ||
ROICexgc | 605.47% | ||
OM | 21.63% | ||
PM (TTM) | 18.31% | ||
GM | 89.64% | ||
FCFM | 17.4% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.42 | ||
Debt/FCF | 1.69 | ||
Debt/EBITDA | 0.97 | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | 6.27 | ||
Cash Conversion | 76.77% | ||
Profit Quality | 95.04% | ||
Current Ratio | 2.2 | ||
Quick Ratio | 2.13 | ||
Altman-Z | -7.17 |